# Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

> **NCT02259725** · PHASE2 · COMPLETED · sponsor: **University of Southern California** · enrollment: 3 (actual)

## Conditions studied

- Gastrinoma
- Glucagonoma
- Insulinoma
- Metastatic Gastrointestinal Carcinoid Tumor
- Pancreatic Polypeptide Tumor
- Pulmonary Carcinoid Tumor
- Recurrent Gastrointestinal Carcinoid Tumor
- Recurrent Islet Cell Carcinoma
- Somatostatinoma

## Interventions

- **DRUG:** regorafenib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02259725
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-16
- **Primary completion:** 2020-08-20
- **Final completion:** 2020-08-20
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2021-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02259725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02259725, "Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02259725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*